hVIVO Future Growth
Future criteria checks 1/6
hVIVO's earnings are forecast to decline at 15.2% per annum while its annual revenue is expected to grow at 4.4% per year. EPS is expected to decline by 15.7% per annum. Return on equity is forecast to be 21.2% in 3 years.
Key information
-15.2%
Earnings growth rate
-15.7%
EPS growth rate
| Life Sciences earnings growth | 26.2% |
| Revenue growth rate | 4.4% |
| Future return on equity | 21.2% |
| Analyst coverage | Good |
| Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 74 | 11 | 14 | 15 | 4 |
| 12/31/2025 | 68 | 10 | 15 | 17 | 7 |
| 12/31/2024 | 62 | 9 | 10 | 14 | 7 |
| 6/30/2024 | 67 | 17 | 7 | 13 | N/A |
| 3/31/2024 | 63 | 17 | 9 | 15 | N/A |
| 12/31/2023 | 59 | 16 | 12 | 17 | N/A |
| 9/30/2023 | 60 | 9 | 16 | 19 | N/A |
| 6/30/2023 | 60 | 3 | 19 | 20 | N/A |
| 3/31/2023 | 56 | 1 | 17 | 18 | N/A |
| 12/31/2022 | 51 | -1 | 15 | 16 | N/A |
| 9/30/2022 | 43 | -1 | 10 | 11 | N/A |
| 6/30/2022 | 35 | -1 | 5 | 7 | N/A |
| 3/31/2022 | 37 | -1 | 3 | 4 | N/A |
| 12/31/2021 | 39 | 0 | 0 | 1 | N/A |
| 9/30/2021 | 39 | -2 | 1 | 2 | N/A |
| 6/30/2021 | 39 | -3 | 2 | 4 | N/A |
| 3/31/2021 | 30 | -7 | 3 | 4 | N/A |
| 12/31/2020 | 22 | -11 | 3 | 4 | N/A |
| 9/30/2020 | 16 | -11 | -1 | -1 | N/A |
| 6/30/2020 | 10 | -11 | -6 | -5 | N/A |
| 3/31/2020 | 7 | -8 | -4 | -4 | N/A |
| 12/31/2019 | 3 | -6 | -3 | -3 | N/A |
| 6/30/2019 | N/A | -2 | -1 | -1 | N/A |
| 3/31/2019 | N/A | -1 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRO's earnings are forecast to decline over the next 3 years (-15.2% per year).
Earnings vs Market: CRO's earnings are forecast to decline over the next 3 years (-15.2% per year).
High Growth Earnings: CRO's earnings are forecast to decline over the next 3 years.
Revenue vs Market: CRO's revenue (4.4% per year) is forecast to grow slower than the German market (5.6% per year).
High Growth Revenue: CRO's revenue (4.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRO's Return on Equity is forecast to be high in 3 years time (21.2%)